Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-mutated Acute Myeloid Leukemia”

94 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 94 results

Not applicableNo Longer AvailableNCT03114228
What this trial is testing

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Who this might be right for
FLT3-mutated Acute Myeloid Leukemia
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02400281
What this trial is testing

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Who this might be right for
Acute Myeloid Leukemia
Arog Pharmaceuticals, Inc. 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT05520567
What this trial is testing

Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07726576
What this trial is testing

Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
University Hospital, Bordeaux 41
Early research (Phase 1)Active Not RecruitingNCT05546580
What this trial is testing

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Oryzon Genomics S.A. 50
Large-scale testing (Phase 3)Not Yet RecruitingNCT07425808
What this trial is testing

FLT3-ITD Targeted Therapy in Fit AML Patients

Who this might be right for
AML (Acute Myeloid Leukemia)
European Organisation for Research and Treatment of Cancer - EORTC 230
Early research (Phase 1)Looking for participantsNCT06366789
What this trial is testing

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc. 150
Testing effectiveness (Phase 2)Study completedNCT03622541
What this trial is testing

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Who this might be right for
FLT3-ITD MutationAML
The University of Hong Kong 46
Early research (Phase 1)Looking for participantsNCT07162116
What this trial is testing

Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 45
Testing effectiveness (Phase 2)Looking for participantsNCT05010122
What this trial is testing

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center 42
Early research (Phase 1)Looking for participantsNCT06222580
What this trial is testing

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more
Uma Borate 30
Not applicableNo Longer AvailableNCT03409081
What this trial is testing

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07755202
What this trial is testing

Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

Who this might be right for
Acute Myeloid LeukemiaAML With FLT3 Mutation
Florian Kuchenbauer 20
Not applicableNo Longer AvailableNCT03746912
What this trial is testing

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
Daiichi Sankyo
Not applicableStudy completedNCT03047083
What this trial is testing

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Who this might be right for
Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc. 1,027
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Testing effectiveness (Phase 2)Active Not RecruitingNCT03591510
What this trial is testing

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Who this might be right for
FLT3-mutated Acute Myeloid Leukemia
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Ended earlyNCT03333486
What this trial is testing

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Leukemia in RemissionAcute Lymphoblastic Leukemia+34 more
Roswell Park Cancer Institute 31
Large-scale testing (Phase 3)Looking for participantsNCT07463651
What this trial is testing

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-ITD MutationAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University 594
Testing effectiveness (Phase 2)Active Not RecruitingNCT04062266
What this trial is testing

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Who this might be right for
Acute Myeloid Leukemia in RemissionFLT3 Gene MutationHematologic and Lymphocytic Disorder+3 more
M.D. Anderson Cancer Center 50
Next Page